Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › H2020

TRICARIX · Minimally invasive transcatheter system for tricuspid heart valve replacement

H2020Status: CLOSED1 December 201830 November 2022EU funding €2,477,362Call H2020-EIC-SMEInst-2018-2020

TRiCares is a medical technology company with the mission to develop and commercialize innovative minimally invasive (transcatheter) solutions replacing high-risk open-heart surgeries for treatment of heart valve diseases. Heart valve diseases are among the most serious cardiac complications affecting >12.7 million patients in Europe. Cardiac surgeons are urgently seeking for a low-risk minimally invasive solution to treat annually >300,000 patients with tricuspid heart valve disease, who are currently simply dying because of having no relevant therapeutic option. TRiCares has uniquely addressed technological challenges associated with tricuspid heart valve disease treatment- the company has developed the first-of-its-kind medical device for tricuspid heart valve replacement (TRICARIX) based on a proprietary dual-stent prosthesis platform.The product addresses a fast-growing transcatheter heart valve replacement/repair market, that is driven by the increasing demand to treat heart valve diseases in the aging population. As no such solution is available for tricuspid valve, introduction of the TRICARIX will create a novel market segment with estimated total market potential of €1 billion in Europe only. The company’s strategy has been built along the regulatory route to obtain CE-marking for the TRICARIX medical device in 2021. TRiCares is led by experienced entrepreneur and experts with successful track record of bringing medical devices to market, including the first European transcatheter aortic valve replacement system in 2012. TRiCares seeks SMEInstr funding to reach the critical First-In-Man study milestone (total costs-of the project €4.3 million) that will greatly facilitate follow-up capital investments to finance the final large-scale efficacy/safety clinical study. CE-marking will position the product/company for a licensing agreement with a global medical device company to ensure effective marketing and clinical implementation of the device.

Consortium · 2 organisations

coordinator

TRICARES GMBH

DE · €2,477,362

thirdParty

TRICARES SAS

FR

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.